Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 532

1.

Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.

Li L, Hao X, Qin J, Tang W, He F, Smith A, Zhang M, Simeone DM, Qiao XT, Chen ZN, Lawrence TS, Xu L.

Gastroenterology. 2014 Apr;146(4):1108-18. doi: 10.1053/j.gastro.2013.12.035.

2.

Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.

Matzke-Ogi A, Jannasch K, Shatirishvili M, Fuchs B, Chiblak S, Morton J, Tawk B, Lindner T, Sansom O, Alves F, Warth A, Schwager C, Mier W, Kleeff J, Ponta H, Abdollahi A, Orian-Rousseau V.

Gastroenterology. 2016 Feb;150(2):513-25.e10. doi: 10.1053/j.gastro.2015.10.020.

PMID:
26597578
3.

SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells.

Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH, Chang SC, Teng HW, Yang SH, Lan YT, Chiou SH, Wang HW.

Gastroenterology. 2011 Jul;141(1):279-91, 291.e1-5. doi: 10.1053/j.gastro.2011.04.008.

PMID:
21640118
4.

HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s.

Li L, Tang W, Wu X, Karnak D, Meng X, Thompson R, Hao X, Li Y, Qiao XT, Lin J, Fuchs J, Simeone DM, Chen ZN, Lawrence TS, Xu L.

Clin Cancer Res. 2013 Dec 15;19(24):6703-15. doi: 10.1158/1078-0432.CCR-13-0621.

5.
6.

Expression of CD44 in pancreatic cancer and its significance.

Li XP, Zhang XW, Zheng LZ, Guo WJ.

Int J Clin Exp Pathol. 2015 Jun 1;8(6):6724-31.

7.

Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.

Niess H, Camaj P, Renner A, Ischenko I, Zhao Y, Krebs S, Mysliwietz J, Jäckel C, Nelson PJ, Blum H, Jauch KW, Ellwart JW, Bruns CJ.

Target Oncol. 2015 Jun;10(2):215-27. doi: 10.1007/s11523-014-0323-z.

PMID:
24950733
8.

Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.

Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, Simeone DM, Zou W, Welling TH.

Gastroenterology. 2014 Dec;147(6):1393-404. doi: 10.1053/j.gastro.2014.08.039.

9.

Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.

Li DD, Fu ZQ, Lin Q, Zhou Y, Zhou QB, Li ZH, Tan LP, Chen RF, Liu YM.

World J Gastroenterol. 2015 Aug 21;21(31):9348-57. doi: 10.3748/wjg.v21.i31.9348.

10.

Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment.

Wei HJ, Yin T, Zhu Z, Shi PF, Tian Y, Wang CY.

Hepatobiliary Pancreat Dis Int. 2011 Aug;10(4):428-34.

11.

CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients.

Li Z, Chen K, Jiang P, Zhang X, Li X, Li Z.

Diagn Pathol. 2014 Apr 8;9:79. doi: 10.1186/1746-1596-9-79.

12.

Dual role of CD44 isoforms in ampullary adenocarcinoma: CD44s predicts poor prognosis in early cancer and CD44ν is an indicator for recurrence in advanced cancer.

Wu CL, Chao YJ, Yang TM, Chen YL, Chang KC, Hsu HP, Shan YS, Lai MD.

BMC Cancer. 2015 Nov 16;15:903. doi: 10.1186/s12885-015-1924-3.

13.

Influence of interferon-α on the expression of the cancer stem cell markers in pancreatic carcinoma cells.

Zhu Y, Karakhanova S, Huang X, Deng SP, Werner J, Bazhin AV.

Exp Cell Res. 2014 Jun 10;324(2):146-56. doi: 10.1016/j.yexcr.2014.03.020.

PMID:
24726912
14.

Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.

Jiang SH, Wang Y, Yang JY, Li J, Feng MX, Wang YH, Yang XM, He P, Tian GA, Zhang XX, Li Q, Cao XY, Huo YM, Yang MW, Fu XL, Li J, Liu DJ, Dai M, Wen SY, Gu JR, Hong J, Hua R, Zhang ZG, Sun YW.

Oncotarget. 2016 Jan 26;7(4):4226-40. doi: 10.18632/oncotarget.6772.

15.

ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.

Shin HW, Choi H, So D, Kim YI, Cho K, Chung HJ, Lee KH, Chun YS, Cho CH, Kang GH, Kim WH, Park JW.

Gastroenterology. 2014 Aug;147(2):430-442.e8. doi: 10.1053/j.gastro.2014.04.047.

PMID:
24846398
16.

CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance.

Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ, Yoon SS.

Clin Cancer Res. 2014 Aug 1;20(15):3974-88. doi: 10.1158/1078-0432.CCR-14-0011.

17.

Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1.

Bao B, Azmi AS, Aboukameel A, Ahmad A, Bolling-Fischer A, Sethi S, Ali S, Li Y, Kong D, Banerjee S, Back J, Sarkar FH.

J Biol Chem. 2014 May 23;289(21):14520-33. doi: 10.1074/jbc.M113.532887.

18.

The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival.

Deng J, He M, Chen L, Chen C, Zheng J, Cai Z.

PLoS One. 2013 Oct 8;8(10):e76450. doi: 10.1371/journal.pone.0076450.

19.

Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.

Geng S, Guo Y, Wang Q, Li L, Wang J.

Arch Dermatol Res. 2013 Jan;305(1):35-47. doi: 10.1007/s00403-012-1260-2.

PMID:
22740085
20.

Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.

Palagani V, El Khatib M, Kossatz U, Bozko P, Müller MR, Manns MP, Krech T, Malek NP, Plentz RR.

PLoS One. 2012;7(10):e46514. doi: 10.1371/journal.pone.0046514.

Items per page

Supplemental Content

Support Center